Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Home-based cognitive behavioural therapy for families of young children with cancer (FAMOS): A nationwide randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia†

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Data on piperacillin-tazobactam pharmacokinetics and optimal dosing in children with cancer and fever are limited. Our objective was to investigate piperacillin pharmacokinetics and the probability of target attainment (PTA) with standard intermittent administration (IA), and to simulate PTA in other dosing regimens.

PROCEDURE: This prospective pharmacokinetic study was conducted from April 2016 to January 2018. Children with cancer receiving empiric piperacillin-tazobactam to treat infections were included. Piperacillin-tazobactam 100 mg/kg was infused over 5 min every 8 hours (IA). An optimized sample schedule provided six blood samples per subject for piperacillin concentration determination. The evaluated targets included: (1) 100% time of free piperacillin concentration above the minimum inhibitory concentration (fT > MIC) and (2) 50% fT > 4× MIC. MIC50 and MIC90 were defined based on an intrainstitutional MIC range.

RESULTS: A total of 482 piperacillin concentrations were obtained from 43 children (aged 1-18 years) during 89 fever episodes. Standard IA resulted in insufficient target attainment, with significant differences in piperacillin pharmacokinetics for different body weights. Median fT > MIC was 61.2%, 53.5%, and 36.3% for MIC50 (2.0 mg/L), MIC90 (4.0 mg/L), and breakpoint for Pseudomonas aeruginosa (16.0 mg/L), respectively. Correspondingly, the median fT > 4× MIC was 43%, 36.3%, and 20.1%. Simulations showed that only continuous infusion reached a PTA of 95% for MIC = 16.0 mg/L, while extended infusion lasting half of the dosing interval reached a PTA of 95% for MIC ≤ 8 mg/L.

CONCLUSIONS: Our data revealed insufficient PTA with standard IA of piperacillin-tazobactam in children with cancer and fever. Alternative dosing strategies, preferably continuous infusion, are required to ensure adequate PTA.

Original languageEnglish
JournalPediatric Blood & Cancer
Volume66
Issue number6
Pages (from-to)e27654
ISSN1545-5009
DOIs
Publication statusPublished - Jun 2019

    Research areas

  • Adolescent, Anti-Bacterial Agents/administration & dosage, Body Weight, Child, Child, Preschool, Dose-Response Relationship, Drug, Female, Fever/drug therapy, Follow-Up Studies, Humans, Infant, Infusions, Intravenous, Male, Monte Carlo Method, Neoplasms/complications, Piperacillin/administration & dosage, Prognosis, Prospective Studies, Tissue Distribution

ID: 61318643